NOTICE: This website is no longer updated and the resources on this site are outdated.
If you have questions about previously published Ontario COVID-19 Science Advisory Table resources, please email communications@oahpp.ca.
SCIENCE BRIEFS.
Informing Ontario’s response to COVID-19
Infectious Diseases & Clinical Care
-
Understanding the Post COVID-19 Condition (Long COVID) in Adults and the Expected Burden for Ontario
-
Severe Acute Hepatitis in Children of Unknown Etiology
-
Paxlovid for a Patient on a DOAC
-
Nirmatrelvir/Ritonavir (Paxlovid): What Prescribers and Pharmacists Need to Know
-
Paxlovid for a Patient on a DOAC
-
Therapeutic Management of Residents of Long-term Care Homes with COVID-19
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Evidence-Based Recommendations on the Use of Nirmatrelvir/Ritonavir (Paxlovid) for Adults in Ontario
-
Nirmatrelvir/Ritonavir (Paxlovid): What Prescribers and Pharmacists Need to Know
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Nirmatrelvir/Ritonavir (Paxlovid): What Prescribers and Pharmacists Need to Know
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Fluvoxamine: What Prescribers and Pharmacists Need to Know
-
Baricitinib for Hospitalized Patients with COVID-19
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Evidence-Based Recommendations on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies (Casirivimab + Imdevimab, and Sotrovimab) for Adults in Ontario
-
Evidence-Based Use of Therapeutics for Ambulatory Patients with COVID-19
-
Evidence-Based Recommendations on the Use of Casirivimab + Imdevimab, and Sotrovimab for Adults in Ontario
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Understanding the Post COVID-19 Condition (Long COVID) and the Expected Burden for Ontario
-
The Incidence, Severity, and Management of COVID-19 in Critically Ill Pregnant Individuals
-
The Impact of the COVID-19 Pandemic on Opioid-Related Harm in Ontario
-
Heparin Anticoagulation for Hospitalized Patients with COVID-19
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Drugs and COVID-19: Information for Patients and Healthcare Professionals
-
Clinical Practice Guidelines Webinar: Medications for Outpatients with COVID-19
-
Ivermectin to Prevent Disseminated Strongyloides Infection in Patients with COVID-19
-
Risk of Vaccine-Induced Thrombotic Thrombocytopenia (VITT) following the AstraZeneca/COVISHIELD Adenovirus Vector COVID-19 Vaccines
-
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in the Outpatient Setting
-
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in Emergency Department and Inpatient Settings
-
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination: Lay Summary
-
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Following Adenovirus Vector COVID-19 Vaccination
-
Remdesivir for Hospitalized Patients with COVID-19
-
Clinical Practice Guidelines Webinar: Tocilizumab
-
Strategies to Manage Tocilizumab Supply During the COVID-19 Pandemic
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in Emergency Department and Inpatient Settings
-
Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) following AstraZeneca COVID-19 Vaccination: Interim Guidance for Healthcare Professionals in the Outpatient Setting
-
Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) Following AstraZeneca COVID-19 Vaccination: Lay Summary
-
Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) Following AstraZeneca COVID-19 Vaccination
-
Tocilizumab for Hospitalized Patients with COVID-19
-
Clinical Practice Guideline Summary: Recommended Drugs and Biologics in Adult Patients with COVID-19
-
Decrease in Antibodies Against SARS-CoV-2 Over Time and Current Role of Serological Testing
-
Dexamethasone in Patients Hospitalized for COVID-19